With over 80 key companies active in the RNA therapies space, the market is projected to grow due to advancements in mRNA, siRNA, and antisense oligonucleotide-based therapies. Emerging RNA-based ...

The hold, which was made in response to a serious adverse event report, could impact the company’s plans to start a Phase 3 trial of a combination shot for COVID-19 and influenza.

The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.

Detailed price information for Cosciens Biopharma Inc (CSCI-T) from The Globe and Mail including charting and trades.

The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.

QUESTION: Although it says right on the package of baking soda that you can use it for heartburn, if you choose to use it, ...

A staggering 800% increase in licensing agreement deal values for messenger ribonucleic acid (mRNA)-based innovator ...

Ahead of the first Labour budget for 14 years, the Association of the British Pharmaceutical Industry (ABPI) has outlined the key measures needed to improve UK life science competitiveness, boost UK R ...

GSK and CureVac restructured their 2020 collaboration into a new licensing agreement worth up to $1.57 billion in July 2024.

we generate license revenue from a limited number of distribution and supply agreements; the pharmaceutical industry is highly competitive with new competing product entrants; requirements for ...

Akums Drugs and Pharmaceuticals rallied 3.06% to Rs 908 after the company announced that it has entered into a license & distribution ... Akums Drugs and Pharmaceuticals is a pharmaceutical contract ...

Under the agreement, NuProbe has the option for an exclusive global license to the panel outside of China for ... and aligns with many key drug targets under development by large pharma. NuProbe Chief ...